BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives Consensus Rating of “Moderate Buy” from Analysts
by Amy Steele · The Cerbat GemShares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) have been given an average recommendation of “Moderate Buy” by the four research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $37.50.
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioXcel Therapeutics in a research note on Wednesday, October 8th.
View Our Latest Analysis on BioXcel Therapeutics
Institutional Trading of BioXcel Therapeutics
Several large investors have recently modified their holdings of BTAI. Diversify Wealth Management LLC acquired a new position in shares of BioXcel Therapeutics during the 2nd quarter valued at $27,000. XTX Topco Ltd acquired a new position in shares of BioXcel Therapeutics during the second quarter valued at about $42,000. Goldman Sachs Group Inc. acquired a new position in shares of BioXcel Therapeutics during the first quarter valued at about $50,000. Geode Capital Management LLC boosted its position in shares of BioXcel Therapeutics by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 28,182 shares of the company’s stock worth $51,000 after purchasing an additional 6,120 shares in the last quarter. Finally, Foundations Investment Advisors LLC acquired a new stake in shares of BioXcel Therapeutics in the 3rd quarter valued at about $76,000. Institutional investors and hedge funds own 30.68% of the company’s stock.
BioXcel Therapeutics Stock Performance
BioXcel Therapeutics stock opened at $1.84 on Thursday. BioXcel Therapeutics has a 52-week low of $1.17 and a 52-week high of $8.08. The firm has a 50 day moving average price of $1.88 and a two-hundred day moving average price of $2.55. The firm has a market cap of $40.24 million, a price-to-earnings ratio of -0.19 and a beta of 0.21.
BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($2.18) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.64). The firm had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.20 million. As a group, equities research analysts predict that BioXcel Therapeutics will post -24.39 EPS for the current fiscal year.
About BioXcel Therapeutics
BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.
BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.